Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulation, 2015 , we hereby inform you that the Board of Directors of the Company at its meeting held on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rekvina Laboratories Ltd reported standalone unaudited results for Q3 FY26 (quarter ended 31 Dec 2025) with revenue from operations of Rs. 34.56 lakhs, up from Rs. 19.62 lakhs in the previous quarter (Q2 FY26). For the nine months ended 31 Dec 2025, total revenue stood at Rs. 54.18 lakhs, while the company posted a loss before tax of Rs. 19.42 lakhs (vs Rs. 9.43 lakhs loss in the same nine-month period last year). Total expenses for the nine months were Rs. 73.60 lakhs, well above revenue, indicating the company is still spending more than it earns. Basic and diluted EPS for the quarter stood at Rs. (0.21) and for nine months at Rs. (0.32). The statutory auditor M. Shah & Co. issued a clean (unqualified) limited review report with no qualifications, adverse comments, or emphasis of matter.
Revenue is growing sequentially but the company remains in losses with expenses still outpacing income, which is a negative signal for shareholders in the short term. The clean auditor review is a relief, but persistent losses and negative EPS suggest the stock remains a high-risk bet until the company achieves profitability.